ArticleInternational journal of surgery (London, England)2026
Artificial intelligence-driven pharmacovigilance analysis of polypharmacy and adverse events in breast cancer survivors treated with antidepressants.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Observational
- Drug-induced adverse events in modern pharmacotherapy: mechanisms, clinical manifestations, and implications for risk assessment and management.Frontiers in pharmacology · 2026Review
- Active monitoring vs. spontaneous reporting of antineoplastic drug-related adverse drug reactions: evidence from the Chinese hospital pharmacovigilance system.Frontiers in health services · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer survivors often require concurrent treatment with antidepressants and anticancer drugs, raising concerns about potential drug-drug interactions and complex safety issues.
methodsThis retrospective pharmacovigilance study analyzed adverse event (AE) reports from the FDA Adverse Event Reporting System database spanning from 2014 to 2024. The analysis focused on breast cancer survivors who were receiving five or more concomitant medications and had reported two or more AEs. An artificial intelligence-driven clustering methodology was employed to identify distinct patterns of AE co-reporting.
resultAmong 12 076 eligible patients, representing 255 020 medication records and 89 369 AE records, three distinct patient subgroups (2.1% of the total) with unique AE co-reporting profiles were identified. The patients in Cluster 1, predominantly middle-aged males, mainly treated with mirtazapine, antipsychotics, chemotherapy, and anti-HER2 monoclonal antibodies, showed high co-reporting rates for gastrointestinal symptoms, extrapyramidal disorders, peripheral neuropathy, and seizures. The patients in Cluster 2, comprising young females, mainly used citalopram combined with chemotherapy and anti-HER2 drugs, co-reported severe gastrointestinal AEs. The patients in Cluster 3, consisting of middle-aged to elderly females, mainly received citalopram, chemotherapy, anti-HER2 monoclonal antibodies, and steroid hormone drugs exhibited extremely high co-reporting rates of respiratory AEs.
conclusionCertain polypharmacy regimens with antidepressants in specific breast cancer survivor subgroups may lead to complex safety signals. Personalized risk evaluation and vigilant medication safety strategies are crucial for these distinct, non-representative patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.